Dyslipidemia Clinical Trials

27 recruiting

Dyslipidemia Trials at a Glance

71 actively recruiting trials for dyslipidemia are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Not Applicable with 28 trials, with the heaviest enrollment activity in Seoul, Athens, and Beijing. Lead sponsors running dyslipidemia studies include University of Georgia, Harvard School of Public Health (HSPH), and CRISPR Therapeutics AG.

Browse dyslipidemia trials by phase

Treatments under study

About Dyslipidemia Clinical Trials

Looking for clinical trials for Dyslipidemia? There are currently 27 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dyslipidemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dyslipidemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 71 trials

Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

Healthy ParticipantsDyslipidemia
AstraZeneca136 enrolled6 locationsNCT06980428
Recruiting

Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa

ObesityCardiovascular DiseasesChronic Kidney Diseases+8 more
Swiss Tropical & Public Health Institute1,200 enrolled1 locationNCT05881447
Recruiting
Not Applicable

Goal Commitment and Proactive Health Behavior in Chronic Disease Patients

Diabetes MellitusHypertensionDyslipidemia
Xiong Juyang600 enrolled1 locationNCT07552571
Recruiting
Not Applicable

A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

Diabetes MellitusObesityHypertension+2 more
University of Connecticut72 enrolled3 locationsNCT07238556
Recruiting
Not Applicable

Group Medical Visits for Patients With Dyslipidemia

Dyslipidemias
Université de Sherbrooke288 enrolled1 locationNCT07543718
Recruiting

The Bialystok Bariatric Surgery Study

Diabetes MellitusObesityMetabolic Syndrome+1 more
Medical University of Bialystok1,000 enrolled1 locationNCT04634591
Recruiting
Phase 2

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Dyslipidemias
NewAmsterdam Pharma69 enrolled1 locationNCT06496243
Recruiting

Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study

Dyslipidemias
JW Pharmaceutical10,000 enrolled1 locationNCT07523971
Recruiting
Not Applicable

Smartwatch-based Intervention for Cardiovascular Health (SWITCH)

PrehypertensionBorderline Dyslipidemia
Beijing Anzhen Hospital1,400 enrolled3 locationsNCT07372729
Recruiting

Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions

AtherosclerosisDyslipidemia
National Heart, Lung, and Blood Institute (NHLBI)1,500 enrolled1 locationNCT06676046
Recruiting
Phase 1

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled18 locationsNCT07491172
Recruiting
Phase 2

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

Dyslipidemias
Ribocure Pharmaceuticals AB120 enrolled4 locationsNCT06797401
Recruiting
Not Applicable

Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)

Dyslipidemia Associated With Type II Diabetes Mellitus
Sin Gon Kim2,186 enrolled2 locationsNCT07359105
Recruiting
Not Applicable

PILI 'Āina Household

HypertensionType 2 DiabetesOverweight and Obesity+1 more
University of Hawaii210 enrolled2 locationsNCT06526273
Recruiting
Not Applicable

'Ai Pono Cooking Demonstrations

HypertensionType 2 DiabetesOverweight and Obesity+1 more
University of Hawaii1,780 enrolled2 locationsNCT06526650
Recruiting
Not Applicable

Clinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional Study

ObesityHypertensionOverweight+4 more
Universidad Católica San Antonio de Murcia220 enrolled1 locationNCT07447362
Recruiting
Not Applicable

Intermittent Cottonseed Oil Consumption

Nutrition, HealthyOverweight and ObesityDyslipidemia
University of Georgia75 enrolled1 locationNCT07246408
Recruiting
Phase 3

Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia

Type 2 DiabetesDyslipidemia
CMG Pharmaceutical Co. Ltd240 enrolled24 locationsNCT06772168
Recruiting
Early Phase 1

Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity

ObesityDyslipidemias
University of Connecticut130 enrolled1 locationNCT05700916
Recruiting

Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)

Primary Hypercholesterolemia or Mixed Dyslipidemia
Novartis Pharmaceuticals1,500 enrolled4 locationsNCT06770543